In 2017, more than 850 million people were estimated to have chronic kidney disease (CKD), which disproportionately affects low- and middle-income countries.1 Death from CKD is largely due to vascular disease,2 and CKD is an independent risk factor for atherosclerosis.3 The first study showing that statins improve cardiovascular outcomes in people with CKD was reported in 2003,4 with a larger pooled analysis confirming these benefits the following year.5 Subsequently, the Study of Heart and Renal Protection (SHARP) trial of 2011 demonstrated that statin-ezetimibe treatment significantly reduces the risk of cardiovascular events among people with G3a-G5 CKD.